CATALYST: Insights from the Experts to Navigate a Complex and Evolving Landscape in CLL and AML Management
FACULTY
Michael R. Grunwald, MD
Chief, Leukemia Division
Associate Professor, Atrium Health
Department of Hematologic Oncology and Blood Disorders
Levine Cancer Institute
Charlotte, NC
Ryan Jacobs, MD
Department of Hematology, Lymphoma Division
Assistant Professor of Medicine
Levine Cancer Institute/Atrium Health
Charlotte, NC
PROGRAM OVERVIEW
This enduring activity will cover the treatment and management of patients with AML and CLL.
TARGET AUDIENCE
This activity is intended for US-based hematologists, medical oncologists, and other healthcare providers involved in the management of patients with CLL and/or AML.
LEARNING OBJECTIVES
Upon completion of the program, attendees should be able to:
- Determine how genetic and molecular markers aid in determining treatment strategies for patients with either CLL or AML
- Differentiate therapy for the treatment of newly diagnosed or relapsed/refractory (R/R) CLL or AML based on disease‐ and patient‐specific factors and communicate treatment plans using shared decision-making strategies
- Distinguish adverse events associated with either CLL or AML treatment to appropriately prevent and/or manage potential effects
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 2.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the care of patients with AML and CLL.
Credits: 2.0 ANCC Contact Hours.
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 2.0 contact hours of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Michael R. Grunwald, MD receives consulting fees from AbbVie, Agios, Amgen, Astellas, Blueprint Medicines, Bristol Myers Squibb, Cardinal Health, Daiichi Sankyo, Gilead, Incyte, Karius, Pfizer, Premier, Sierra Oncology, and Stemline Therapeutics; receives research funding (institution) from Incyte and Janssen; and has stock ownership in Medtronic.
Ryan Jacobs, MD serves on a speaker bureau for AbbVie, AstraZeneca, Janssen, Pharmacyclics, Secura Bio and TG Therapeutics; serves as consultant for Adaptive, AstraZeneca, Genentech, Secura Bio, and TG Therapeutics; and receives research funding from MEI Pharma Pharmacyclics, Teneobio and TG Therapeutics.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner
The reviewer of this activity has nothing to disclose
Staff, Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP Educational Development for Med Learning Group has nothing to disclose.
Felecia Beachum, Program Manager for Med Learning Group has nothing to disclose.
Deb Gordon, Medical Director for Med Learning Group, owns stock in AbbVie and Merck.
Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes for Med Learning Group has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator for Med Learning Group has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
- Read the CME/CNE information and faculty disclosures.
- Participate in the enduring activity.
- Submit the evaluation form to Med Learning Group.
You will receive your certificate as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making skills before applying any information, whether provided here or by others, for any professional use.
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com
For CME questions, please contact Med Learning Group at info@medlearninggroup.com
RELEASE DATE: November 05, 2021
EXPIRATION DATE: November 05, 2022
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/
Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
